Materials and Methods:
To deliver immune stimulatory adjuvants to the TDLN, we implemented poly(propylene) sulfide (PPS)-core nanoparticles (NPs) that target immune cells within the TDLN in an in vivo murine melanoma model when administered in the limb ipsilateral (i.l.) but not contralateral (c.l.) to the tumor ( Figure 1A-B) . NPs are composed of the polymer polypropylene sulfide (PPS) to form the hydrophobic core, surface stabilized with Pluronic 2 . We incorporated either of two immune modulatory Adjs into the NPs by solvent dispersion or pyridyl disulfide covalent conjugation. First, we explored the use of paclitaxel (PXL), a widely used chemotherapeutic, that has more recently been described to enhance vaccine efficacy and function as a toll-like receptor (TLR) 4 ligand. Second, we implemented unmethylated DNA oligonucleotides (CpG) that induce robust inflammatory immune reactions via TLR9 ligand activity. We assessed the effect of targeted delivery of immunomodulatory Adjs using the NP technology to the TDLN and their induced immune response and resulting affect on tumor progression.
Results and Discussion:
Both types of Adj-NPs, PXLNPs and CpG-NPs, were capable of inducing immune reactions in vitro, as indicated by CD11c + cell maturation and inflammatory cytokine IL-12 production. When applied to the limb of mice i.l. to the tumor daily after tumor establishment at low doses (~0.5 mg/kg and 2.5 μg/mouse for PXL and CpG, respectively), Adj-NPs slowed tumor growth ( Figure 1A ) and reshaped the immune milieu inside both the TDLN and tumor ( Figure  1B Conclusions: Together, this work implicates the TDLN as a novel drug delivery target for immunotherapy of solid tumors. Moreover, these data indicate that biomaterials engineering strategies can enhance the potential of Adjs in the effective activation of immune reactions against tumors for cancer immunotherapy applications. 
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